iCo Therapeutics Inc.

  • ISIN: CA45107J1057
  • Land: .

Nachricht vom 15.06.2017 | 22:15

iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset

DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous

15.06.2017 / 22:15
The issuer is solely responsible for the content of this announcement.

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017.

  • Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a pre-clinical proof of concept in several animal models confirms efficacy in reducing IOP. It has possible neuroprotective activity and the potential for novel and more effective combinations with prostaglandin analogs.
    • To date 29 patents have been issued
    • Asset addresses a market that is estimated to grow to $5 billion by 2018
      (Source: 2014 Market Scope Estimates; Courtesy Dave Harman. http://market-scope.com/)
  • Purpose of the FDA Type B pre-IND meeting will be to discuss questions related to the program development for SVT-63 or SVT-88 as topical ophthalmic solutions for the treatment of Primary Open-Angle Glaucoma (POAG) or ocular hypertension, including study designs in monotherapy and combination clinical trials as well as acceptable visual function endpoints for exploration of potential neuroprotective properties of the two compounds.
  • In a previous study patients administered an inhibitor 11B-HSD, mediated via 11B-HSD1 in the ciliary epithelium, lowered IOP in patients with ocular hypertension (S. Rauz et al. QJ Med 2003; 96: 481-490)
  • iCo has the worldwide exclusive option to acquire the asset outright, with diligence activities during the option period focusing on commercialization of the asset

Stated Andrew Rae, CEO of iCo Therapeutics, 'we are excited to have arrived at this inflection point with our colleagues at Salvat and look forward to important guidance regarding a clinical path forward for a potential first in class glaucoma candidate'.

For more information please refer to:

About Salvat

Laboratorios SALVAT is a privately owned pharmaceutical group closely identified with technological innovation and strongly committed to R&D. SALVAT's headquartered are located in Barcelona (Spain) and its US subsidiary, SALVAT USA, is located in Miami, FL. Founded in 1955, SALVAT is present in over 60 countries and keeps strengthening its international presence through the licensing of its own developments. The company launched CETRAXAL® (ciprofloxacin 0.2 %) otic solution in the US in 2009 and received FDA approval for OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution in April 2016.

Additional information regarding Laboratorios SALVAT and its products is available at www.salvatbiotech.com

About iCo Therapeutics

iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company's core focus areas and if so the Company will seek to capture further value via partnerships, such as its partnership with Immune Pharmaceuticals (NASDAQ: IMNP), which is in several Phase 2 studies involving iCo-008. iCo shares trade on the TSX Venture Exchange under the symbol 'ICO' and on the OTCQB under the symbol 'ICOTF'.

For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking statements' within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will,' and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Program contacts:

Alberto Bueno
Chief Executive Officer
Laboratorios SALVAT

Francesc Rosell
International Director

Andrew Rae
Chief Executive Officer
iCo Therapeutics Inc.
1-778-772-7775 (c)

Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/27456

15.06.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Übernahme im Fokus

Übernahmeangebot für die Epigenomics AG

Die Summit Hero Holding GmbH hat die Angebotsunterlage zum freiwilligen öffentlichen Übernahmeangebot für alle ausstehenden Aktien der Epigenomics AG veröffentlicht. Vorstand und Aufsichtsrat der Epigenomics AG begrüßen das Übernahmeangebot und empfehlen den Aktionären die Annahme.

Mit einer attraktiven Bar-Prämie von rund 50 % können sich die Epigenomics-Aktionäre eine der höchsten Übernahmeprämien seit 2014 in Deutschland sichern. Die Annahme des Übernahmeangebots ist bis zum 7. Juli 2017 möglich.

GBC im Fokus

Fintech-Spezialist für den afrikanischen Markt

Das Fintech-Unternehmen MyBucks S.A. bietet den Kunden aus der Sub-Sahara-Region durch den Einsatz moderner Technologien einen Zugang zu Finanzprodukten- und dienstleistungen. Hierbei handelt es sich in erster Linie um nicht besicherte Kredite, welche über Onlinekanäle beantragt und in Anspruch genommen werden. Die Grundlage für die Geschäftstätigkeit stellt die selbstentwickelte Technologie dar, wodurch Kunden innerhalb weniger Minuten eine Kreditentscheidung erhalten. Wir gehen von einer Fortsetzung der dynamischen Unternehmensentwicklung aus und haben einen fairen Wert von 26,70 € je Aktie und damit hohes Kurspotenzial ermittelt. Wir vergeben das Rating KAUFEN.

News im Fokus

RWE Aktiengesellschaft: RWE-Vorstand beabsichtigt Ausschüttung einer Sonderdividende von 1,00 EUR je Aktie aus der Rückerstattung der Kernbrennstoffsteuer

23. Juni 2017, 13:21

Aktuelle Research-Studie

curasan AG

Original-Research: curasan AG (von Montega AG): n.a.

23. Juni 2017